Avalo Therapeutics Inc. (NASDAQ: AVTX)
$12.40
+0.2400 ( +1.97% ) 14.3K
Avalo Therapeutics Inc is a clinical stage biotechnology company focused on the treatment of immune dysregulation. The company's lead asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).
Market Data
Open
$12.40
Previous close
$12.16
Volume
14.3K
Market cap
$13.08M
Day range
$11.78 - $12.75
52 week range
$3.95 - $84.79
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
10-q/a | Quarterly Reports | 70 | Jul 11, 2024 |
8-k | 8K-related | 15 | Jul 09, 2024 |
def | Proxies and info statements | 7 | Jun 27, 2024 |
ars | Annual reports | 1 | Jun 27, 2024 |
4 | Insider transactions | 1 | Jun 25, 2024 |
3 | Insider transactions | 2 | Jun 25, 2024 |
8-k | 8K-related | 17 | Jun 24, 2024 |
8-k/a | 8K-related | 16 | Jun 24, 2024 |
8-k | 8K-related | 39 | Jun 24, 2024 |
pre | Proxies and info statements | 7 | Jun 07, 2024 |